Therapeutics
Examples of evidence include:
Related pages
- Diabetes control and complications trial
- CALM study
- UK Prospective Diabetes Study
- Orlistat in obese type II diabetics
- Heart Outcomes Prevention Evaluation Study
- MRC/BHF Heart Protection Study ( HPS )
- Proactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study
- EMPA - REG trial - empagliflozin in type 2 diabetes patients with high cardiovascular risk (EMPAREG)
- CANVAS Program - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial
- SUSTAIN-6 - subcutaneous semaglutide and cardiovascular outcomes in type 2 Diabetes
- DECLARE - TIMI 58 - dapagliflozin and cardiovascular outcomes in type 2 diabetes
- CREDENCE - canagliflozin and renal outcomes in type 2 diabetes (diabetic) and nephropathy
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF)
- Diabetes Remission Clinical Trial (DiRECT) using diet in diabetes
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.